NasdaqGS - Nasdaq Real Time Price ? USD Atara Biotherapeutics, Inc. (ATRA) Follow Compare 11.47 +0.86 (+8.11%) At close: 4:00 PM EST 11.47 0.00 (0.00%) After hours: 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations Atara Biotherapeutics ( NASDAQ:ATRA ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.2m (up by... Simply Wall St. ? 7 days ago ATRA +8.11% Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference THOUSAND OAKS, Calif., November 13, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST. Business Wire ? 9 days ago ATRA +8.11% Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 22.28% and 74.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 10 days ago ATRA +8.11% Atara Biotherapeutics: Q3 Earnings Snapshot THOUSAND OAKS, Calif. AP) — Atara Biotherapeutics Inc. ATRA) on Tuesday reported a loss of $21.9 million in its third quarter. Associated Press Finance ? 10 days ago ATRA +8.11% Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress THOUSAND OAKS, Calif., November 12, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2024, recent business highlights, and key upcoming milestones. Business Wire ? 10 days ago ATRA +8.11% Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 THOUSAND OAKS, Calif., November 05, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. Business Wire ? 17 days ago ATRA +8.11% Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zacks ? last month ATRA +8.11% Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) THOUSAND OAKS, Calif., October 04, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,500 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Business Wire ? last month ATRA +8.11% After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January —?while eyeing the next frontier. Pharma Voice ? last month ATRA +8.11% Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc On September 3, 2024, Redmile Group, LLC (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 579,541 shares of Atara Biotherapeutics Inc (NASDAQ:ATRA). This transaction not only reflects the firm's strategic investment approach but also highlights its confidence in the biotechnology sector. GuruFocus.com ? 2 months ago ATRA +8.11% Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference THOUSAND OAKS, Calif., September 04, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 6:30 Business Wire ? 2 months ago ATRA +8.11% Atara Biotherapeutics Announces $36 Million Registered Direct Offering THOUSAND OAKS, Calif., September 03, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into definitive agreements for the issuance and sale of 758,900 shares of its common stock at a purchase price of $8.25 per share and the issuance and sale of pre-funded warrants to pu Business Wire ? 2 months ago ATRA +8.11% Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price It's shaping up to be a tough period for Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ), which a week ago released some... Simply Wall St. ? 3 months ago ATRA +8.11% Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations Atara Biotherapeutics ( NASDAQ:ATRA ) Second Quarter 2024 Results Key Financial Results Revenue: US$28.6m (up by... Simply Wall St. ? 3 months ago ATRA +8.11% Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -148% and 40.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago ATRA +8.11% Atara Biotherapeutics: Q2 Earnings Snapshot ATRA) on Monday reported a loss of $19 million in its second quarter. The Thousand Oaks, California-based company said it had a loss of $3.10 per share. The results missed Wall Street expectations. Associated Press Finance ? 3 months ago ATRA +8.11% Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update THOUSAND OAKS, Calif., August 12, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcoming milestones for 2024. Business Wire ? 3 months ago ATRA +8.11% Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference THOUSAND OAKS, Calif., August 07, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate at the Canaccord Genuity 44th Annual Growt Business Wire ? 3 months ago ATRA +8.11% US FDA grants priority review for Pierre Fabre’s EBV+ PTLD A decision by the US regulator under the Prescription Drug User Fee Act is anticipated by 15 January 2025. Pharmaceutical Technology ? 4 months ago ATRA +8.11% FDA priority review advances Atara’s tabelecleucel for viral infection Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US. Pharmaceutical Technology ? 4 months ago ATRA +8.11% GLDAF Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ATRA S&P 500 YTD -10.57% +25.15% 1-Year -9.15% +31.54% 3-Year -97.49% +27.06%
